261 related articles for article (PubMed ID: 33331525)
1. Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão.
Silva AAMD; Lima-Neto LG; Azevedo CMPES; Costa LMMD; Bragança MLBM; Barros Filho AKD; Wittlin BB; Souza BF; Oliveira BLCA; Carvalho CA; Thomaz EBAF; Simões-Neto EA; Leite Júnior JF; Cosme LMSS; Campos MAG; Queiroz RCS; Costa SS; Carvalho VA; Simões VMF; Alves MTSSBE; Santos AMD
Rev Saude Publica; 2020; 54():131. PubMed ID: 33331525
[TBL] [Abstract][Full Text] [Related]
2. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.
He Z; Ren L; Yang J; Guo L; Feng L; Ma C; Wang X; Leng Z; Tong X; Zhou W; Wang G; Zhang T; Guo Y; Wu C; Wang Q; Liu M; Wang C; Jia M; Hu X; Wang Y; Zhang X; Hu R; Zhong J; Yang J; Dai J; Chen L; Zhou X; Wang J; Yang W; Wang C
Lancet; 2021 Mar; 397(10279):1075-1084. PubMed ID: 33743869
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys.
Hallal PC; Hartwig FP; Horta BL; Silveira MF; Struchiner CJ; Vidaletti LP; Neumann NA; Pellanda LC; Dellagostin OA; Burattini MN; Victora GD; Menezes AMB; Barros FC; Barros AJD; Victora CG
Lancet Glob Health; 2020 Nov; 8(11):e1390-e1398. PubMed ID: 32979314
[TBL] [Abstract][Full Text] [Related]
4. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic.
Popova AY; Smirnov VS; Andreeva EE; Babura EA; Balakhonov SV; Bashketova NS; Bugorkova SA; Bulanov MV; Valeullina NN; Vetrov VV; Goryaev DV; Detkovskaya TN; Ezhlova EB; Zaitseva NN; Istorik OA; Kovalchuk IV; Kozlovskikh DN; Kombarova SY; Kurganova OP; Lomovtsev AE; Lukicheva LA; Lyalina LV; Melnikova AA; Mikailova OM; Noskov AK; Noskova LN; Oglezneva EE; Osmolovskaya TP; Patyashina MA; Penkovskaya NA; Samoilova LV; Stepanova TF; Trotsenko OE; Totolian AA
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452512
[TBL] [Abstract][Full Text] [Related]
6. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).
Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP;
Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702
[TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi-challenges in acquiring herd immunity for COVID 19.
Zaidi S; Rizwan F; Riaz Q; Siddiqui A; Khawaja S; Imam M; Naz A; Waheed S; Shamsi T
J Public Health (Oxf); 2021 Apr; 43(1):3-8. PubMed ID: 32940328
[TBL] [Abstract][Full Text] [Related]
8. Seroprevalence of anti-SARS-CoV-2 antibodies 6 months into the vaccination campaign in Geneva, Switzerland, 1 June to 7 July 2021.
Stringhini S; Zaballa ME; Pullen N; Perez-Saez J; de Mestral C; Loizeau AJ; Lamour J; Pennacchio F; Wisniak A; Dumont R; Baysson H; Richard V; Lorthe E; Semaani C; Balavoine JF; Pittet D; Vuilleumier N; Chappuis F; Kherad O; Azman AS; Posfay-Barbe K; Kaiser L; Guessous I;
Euro Surveill; 2021 Oct; 26(43):. PubMed ID: 34713799
[TBL] [Abstract][Full Text] [Related]
9. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
[TBL] [Abstract][Full Text] [Related]
10. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
COVID-19 Cumulative Infection Collaborators
Lancet; 2022 Jun; 399(10344):2351-2380. PubMed ID: 35405084
[TBL] [Abstract][Full Text] [Related]
11. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study.
Álvarez-Antonio C; Meza-Sánchez G; Calampa C; Casanova W; Carey C; Alava F; Rodríguez-Ferrucci H; Quispe AM
Lancet Glob Health; 2021 Jul; 9(7):e925-e931. PubMed ID: 34022148
[TBL] [Abstract][Full Text] [Related]
12. Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020.
Wagner R; Peterhoff D; Beileke S; Günther F; Berr M; Einhauser S; Schütz A; Niller HH; Steininger P; Knöll A; Tenbusch M; Maier C; Korn K; Stark KJ; Gessner A; Burkhardt R; Kabesch M; Schedl H; Küchenhoff H; Pfahlberg AB; Heid IM; Gefeller O; Überla K
Viruses; 2021 Jun; 13(6):. PubMed ID: 34200766
[TBL] [Abstract][Full Text] [Related]
13. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study.
Pastor-Barriuso R; Pérez-Gómez B; Hernán MA; Pérez-Olmeda M; Yotti R; Oteo-Iglesias J; Sanmartín JL; León-Gómez I; Fernández-García A; Fernández-Navarro P; Cruz I; Martín M; Delgado-Sanz C; Fernández de Larrea N; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Larrauri A; Pollán M;
BMJ; 2020 Nov; 371():m4509. PubMed ID: 33246972
[TBL] [Abstract][Full Text] [Related]
14. Seroprevalence of severe acute respiratory syndrome coronavirus 2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned.
Poljak M; Oštrbenk Valenčak A; Štrumbelj E; Maver Vodičar P; Vehovar V; Resman Rus K; Korva M; Knap N; Seme K; Petrovec M; Zupan B; Demšar J; Kurdija S; Avšič Županc T
Clin Microbiol Infect; 2021 Jul; 27(7):1039.e1-1039.e7. PubMed ID: 33838303
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
Pollán M; Pérez-Gómez B; Pastor-Barriuso R; Oteo J; Hernán MA; Pérez-Olmeda M; Sanmartín JL; Fernández-García A; Cruz I; Fernández de Larrea N; Molina M; Rodríguez-Cabrera F; Martín M; Merino-Amador P; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R;
Lancet; 2020 Aug; 396(10250):535-544. PubMed ID: 32645347
[TBL] [Abstract][Full Text] [Related]
16. Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review.
Byambasuren O; Dobler CC; Bell K; Rojas DP; Clark J; McLaws ML; Glasziou P
PLoS One; 2021; 16(4):e0248946. PubMed ID: 33798211
[TBL] [Abstract][Full Text] [Related]
17. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.
Ristić M; Milosavljević B; Vapa S; Marković M; Petrović V
PLoS One; 2021; 16(7):e0254516. PubMed ID: 34242377
[TBL] [Abstract][Full Text] [Related]
19. Dynamics of SARS-CoV-2 seroprevalence during the first year of the COVID-19 pandemic in the Northeast region of Brazil.
de Souza Araújo AA; Quintans-Júnior LJ; Heimfarth L; Schimieguel DM; Corrêa CB; de Moura TR; Cavalcante RCM; Grespan R; de Souza Siqueira Quintans J; Dos Santos DM; da Silva DN; de Oliveira YLM; de Franca MNF; da Conceição Silva M; de Sá DLF; de Carvalho FO; de Souza MF; de Oliveira Góes MA; Santos VS; Martins-Filho PR
Pathog Glob Health; 2023 Jul; 117(5):505-512. PubMed ID: 36094065
[TBL] [Abstract][Full Text] [Related]
20. Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of São Paulo, Brazil.
Tess BH; Granato CFH; Alves MCGP; Pintão MCT; Nunes MC; Rizzatti EG; Reinach FC
Braz J Infect Dis; 2021; 25(4):101604. PubMed ID: 34416142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
